Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
Publishing timestamp: 2024-10-01 18:32:35
Summary
Pfizer announced the voluntary withdrawal of its sickle cell disease therapy, Oxbryta, due to higher risk of deaths and complications in patients. This decision has raised concerns and left patients and doctors scrambling for information and guidance. The withdrawal may impact the development of other treatments for sickle cell disease and raise questions about Pfizer's growth prospects. Additionally, a new cybersecurity bill has been introduced to establish tougher standards in the healthcare sector following a rise in cyberattacks.
Sentiment: MIXED
Tickers: FULC, UNH, AGIO, BLUE, VRTX, PFE,
Keywords: agios pharmaceuticals inc, bluebird bio inc, business news, biotech and pharmaceuticals, fulcrum therapeutics inc, andrew witty, health care industry, unitedhealth group inc, vertex pharmaceuticals inc, hacking, ron wyden, pfizer inc, social issues,